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A B S T R A C T
Prostate cancer is poorly visualized on ultrasonography (US) so that current biopsy requires either a templated
technique or guidance after fusion of US with magnetic resonance imaging. Here we determined the ability for
photoacoustic tomography (PAT) and US followed by texture-based image processing to identify prostate biopsy
targets. K-means clustering feature learning and testing was performed on separate datasets comprised of 1064
and 1197 nm PAT and US images of intact, ex vivo human prostates. 1197 nm PAT was found to not contribute to
the feature learning, and thus, only 1064 nm PAT and US images were used for final feature testing. Biopsy
targets, determined by the tumor-assigned pixels’ center of mass, located 100% of the primary lesions and 67%
of the secondary lesions. In conclusion, 1064 nm PAT and US texture-based feature analysis provided successful
prostate biopsy targets.
1. Introduction
Prostate cancer (PCa) is the most incident, visceral cancer in USA
men. An estimated 164,690 new prostate cancer cases are predicted to
occur in 2018, which is 9.5% of all estimated 2018 cancer occurrences
[1]. The current overall 5-year survival rate is 97.7%, especially when
PCa is discovered at a local stage, but this drops to 30% if the PCa has
metastasized prior to diagnosis [2]. In order to ensure that diagnosis
occurs at the local stage while limiting harm to the patient, serum
prostate-specific antigen (PSA) measurement is recommended as a
screening tool for PCa depending on factors, such as age, family history
and the patient’s preference [3,4]. PSA is produced exclusively by
prostate epithelial cells and can be influenced by benign conditions
including: bacterial prostatitis [5], ejaculation [6], and benign prostatic
hyperplasia [7]. Thus, false positive results from PCa serum PSA
screening commonly occur, which makes a follow-up, confirmatory test
necessary.
Currently to confirm the presence of PCa, histopathology analysis
with Gleason grading must be performed on biopsy samples acquired
from the prostate in order to guide clinical decision making [8].
Gleason grading is based on the microscopic tissue architecture, and the
two major Gleason grades are added to give the Gleason score [9]. The
current clinical standard for acquiring biopsy samples is to perform a
12-core transrectal ultrasound (TRUS)-guided biopsy (TRUS-GB), which
entails following a template to systematically acquire 12 tissue samples
from the prostate [10]. To follow the template protocol, a TRUS probe
guides the biopsy procedure by allowing visualization of the anatomical
locations within the prostate [10,11]. Even with optimization of the
TRUS-GB, false negative results occur in approximately 15–34% of in-
itial biopsy procedures due to the limited, untargeted sampling of the
prostate [12,13].
The combination of the PSA and the TRUS-GB is considered to be
the major contributor to the overtreatment problem for PCa [3]. Since
the biopsied tissue, and not the PSA, currently provides the diagnostic
information to aid in therapeutic decision making [9], the biopsy pro-
cedure needs improvement due to its low sensitivity [14]. As previously
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mentioned, the current gold standard for performing the biopsy is a
systematic approach based on a template [10]. Therefore, providing a
target for the prostate biopsy may help to improve the sensitivity of the
procedure.
The most notable clinical advancement for targeting the prostate
biopsy is the magnetic resonance imaging-fusion biopsy (MRI-FB),
which is currently recommended for patients undergoing repeat biopsy
following an initial negative biopsy [15,16]. For biopsy-naïve patients,
recent conflicting evidence exists regarding the PCa detection rate
when using the MRI-FB compared to TRUS-GB [17–22]. Overall, these
clinical studies show that the MRI-FB alone can reduce the number of
cores needed to achieve the same PCa detection rates as the TRUS-GB
[17,20,22]. Additionally, the MRI-FB has been shown to miss fewer
clinically significant PCa tumors [22]. This reduction in cores needed
and detection of clinically significant PCa tumors can reduce the risk of
side effects and the need for repeat biopsy. However, many pitfalls exist
with this method. Careful calibration is needed to fuse the real-time US
and previously acquired, annotated multiparametric MRI (mpMRI). If
the patient moves after alignment, the calibration must be completed
again. In addition, the mpMRI images are static, and manual pressure
on the prostate during biopsy can distort the tissue compared to the
mpMRI [23]. Other pitfalls include added costs for the mpMRI [24] and
the injected contrast agents, which may be contraindicated in some
patients [25], used in the procedure. Thus, an ideal solution for tar-
geting the PCa biopsy includes endogenous contrast and real-time, co-
incident imaging and analysis.
Since the prostate biopsy is TRUS-guided, photoacoustic tomo-
graphy (PAT), which uses traditional ultrasound (US) transducer arrays
for signal collection [26], is a potential tool to apply clinically in order
to improve the prostate biopsy. In contrast to MRI-FB, PAT has inherent
co-registration with the US imaging channel as the PAT and US images
are sequentially acquired using the same US transducer array. MRI-FB
does have an advantage in imaging resolution and difference in bio-
marker type compared to PAT for prostate biopsy targeting. For PAT,
the imaging resolution is dependent on the US transducer’s imaging
resolution [26]. Since the TRUS probe used for prostate biopsy is ty-
pically a low frequency US transducer with central frequency at ap-
proximately 7MHz [27], the axial resolution is approximately two to
three times lower than the resolution of the mpMRI sequences used for
the MRI-FB [28]. Another potential major difference is that the re-
commended mpMRI utilizes two functional imaging sequences out of
the three total sequences as biomarkers [28], while PAT approaches can
be based on biomarker content [29,30] and/or functional alterations
[31]. Overall, PAT should be investigated as an alternative to MRI-FB
for the purpose of targeting the prostate biopsy.
The photoacoustic signal detected during PAT results when an ab-
sorber interacts with pulsed light in such a way that the energy is
converted to heat, and the resultant local thermodynamic expansion
releases an acoustic wave, which is detectable via an US transducer
[26]. Compared to traditional optical-only imaging techniques, this
allows for deeper imaging of major endogenous absorbers, such as de-
oxygenated and oxygenated hemoglobin, lipid, and water [26,30]. A
few examples of the applications in which these endogenous photo-
acoustic contrast agents have been used are intravascular imaging of
atherosclerotic plaques [32], breast cancer tumor margin assessment
[33], and PCa [34] and breast cancer [35] vascularity. Since PCa is
known to involve angiogenic processes [36], PAT, with hemoglobin as
the endogenous contrast agent [26,30], may be able to identify targets
for the prostate biopsy. Thus, we utilized the 1064 nm output from our
previously published barium nitrite Raman laser [37] to image he-
moglobin in human prostates. Unfortunately, angiogenesis in the
prostate is not specific to PCa [36], while increasing cholesteryl ester,
i.e. lipid, storage has been shown to be a specific biomarker to in-
creasingly aggressive PCa [38]. Therefore, PAT was also performed at
1197 nm, which is an absorption peak for lipid [30,37].
Recent studies have begun applying PAT to the identification of PCa
in human prostates [34,39–41]. Unfortunately, a method of identifying
targets for the prostate biopsy has yet to be achieved without manual
selection of regions of interest (ROI) that rely on intensity-based
thresholding [34,39] or the use of multispectral PAT analysis [39–41]
that would decrease the frame rate. Out of these studies, Rajanna et al.
used deep neural networks to learn features and then identify pixels
representing PCa. This work was completed using a previously pub-
lished PAT dataset of ex vivo human prostates that were sliced into axial
sections prior to five wavelength PAT imaging [39]. The imaging
method ensures uniform light fluence over the anterior-posterior axis of
the tissue, which is currently not possible for prostate PAT in the
clinical setting [34]. Additionally, the feature learning method used is
based on feature learning of gene expression profiles, which can have
hundreds of features [42]. Here, we minimize the PAT channels to 1064
and 1197 nm and acquire the standard US channel. Since feature
learning typically involves 10 s–100 s of features [40,42], we utilize the
“off-the-shelf” K-means clustering feature learning of texture patches,
which has been shown to be effective in single-layer networks [43], for
the purpose of identifying targets for PCa biopsy.
2. Materials and methods
2.1. Prostate specimen inclusion and handling
All work performed followed the approved Institution Review Board
protocol (IUSCC-0581). A total of 9 prostate specimens were imaged in
a room near the Indiana University Hospital surgical suite directly
following radical prostatectomy (Fig. 1). After 10 sterile saline washes
of the external surface, prostates were immobilized using an agar bed
and imaged with PAT and US as described below. Formalin fixation and
whole mount histopathological analysis was then performed by ur-
ogenital pathologist (L.C.) as previously described [44]. De-identified
pathology reports were also provided in addition to the annotated
whole mount histopathology slides.
Fig. 1. Prostate Specimen Handling During Data Collection. (A) Prostate spe-
cimen handling procedure from radical prostatectomy to whole mount histo-
pathology. (B) Image of prostate specimen during PAT and US imaging.
UST+BFB: ultrasound transducer with bifurcated fiber bundle. (C) Image of
prostate specimen depicting position during imaging and the raster scanning
pathway. (D) Representative whole mount histopathology slide. An experi-
enced urogenital pathologist marked the tumor margins and completed the
corresponding histopathology report. These slides are considered ground truth
for image analysis.
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2.2. PAT and US imaging
1064 nm and 1197 nm PAT imaging was performed using a setup
(Fig. 2) with the previously published barium nitrite Raman laser [37]
pumped with a 10 Hz Nd:YAG laser (Continuum, San Jose, CA). A bi-
furcated fiber bundle (Fiber Optic Systems, Inc., Simi Valley, CA) de-
livered the pulsed light at a 30° angle relative to the probe. A C9-5ICT
TRUS probe (Philips, Andover, MA) was used to collect PAT signal and
to perform US imaging with an US system (Verasonics, Kirkland, WA).
The C9-5ICT TRUS probe was designed to include US imaging of the
prostate from the rectal cavity, and thus allowed for imaging of the
prostate’s entire posterior-anterior depth. Experiments were performed
at 55mJ/pulse with a 0.5mm step size while raster scanning. Scanning
was performed in 10min with no averaging applied per frame. Images
were taken in the prostate’s axial plane to match the histopathology
slices’ plane.
2.3. Image and histopathology slice matching
PAT and US images were matched to histopathology slides (n= 40)
by using the US channel alone. Since the PAT and US imaging were
performed in the same plane as the histopathology slices, the prostate
characteristics from the histopathology slides, which included anterior-
posterior length, left-right length, urethral position and perimeter
shape, along with a minimum spacing of 4mm between each prostate’s
histopathology slides, were used to determine the best match between
the histopathology slides and the US channel. The measurements were
taken manually from the histopathology slides [45]. Measurements of
US channel frames were taken using ImageJ [46]. As scanning was
performed in 0.5mm increments, the distance between US channels
was known to ensure at least 4 mm spacing between frames matched to
consecutive histopathology slices.
2.4. Intensity-based analysis of PAT images
ImageJ was used to assess the minimum, average, and maximum
signal intensities for PCa and laterally-matched benign ROIs. The
averaged maximum benign ROI signal intensity was used as the
minimum threshold for PCa-specific signal to determine if intensity
thresholding can be applied to determine targets for the prostate
biopsy.
2.5. Training and testing datasets
The training dataset consisted of six prostate specimens comprising
of 28 total whole mount histopathology slices, while the testing dataset
had three prostate specimens of 12 histopathology slices. Table 1 shows
the specimens’ clinical and pathological distribution. The two datasets
were randomly divided, except for the Gleason 6 case that was speci-
fically added to the training dataset as there was only one case with this
Gleason score.
2.6. Statistical analysis
A minimum of three repetitions were used for all experiments.
Values are represented as averages with standard deviation of sample
for the error. One-way ANOVA was used for hypothesis testing with
Tukey’s HSD post hoc test. The significance level (p) is< 0.05.
3. Results
3.1. Performance of the PAT/US tomography system
In order to collect PAT and US images for testing our proposed
image analysis approach, a PAT setup utilizing a TRUS probe was
needed. Thus, we utilized the C9-5ICT TRUS probe, which is compatible
with our US system. For PA excitation, we utilized a 10 Hz Nd:YAG laser
to pump a barium nitrite Raman laser as we were testing 1064 and
1197 nm [37]. To deliver the pulsed light to the tissue, a bifurcated
fiber bundle was fixed to the US probe at the end, parallel to the
transducer array, with a 30° angle relative to the probe, thereby
creating a focus of approximately 1 cm by 2 cm at 1 cm from the US
transducer (Fig. 3A). The surface area per bifurcated fiber bundle end is
Fig. 2. Photoacoustic and Ultrasound Tomography Imaging Setup. (A) Schematic of PAT and US imaging system. M1: 45° reflective mirror; M2: flip-mounted 45°
reflective mirror; M3: resonator end mirror; M4: output coupler; PBS: polarizing beam splitter; HWP: half wave plate; QWP: quarter wave plate; BdN: barium dinitrite
crystal; BFB: bifurcated fiber bundle; UST: ultrasound transducer; DAQ: data acquisition system. (B) Image of PAT and US imaging system at location in Indiana
University Hospital near surgical suite for optimized tissue handling.
Table 1
Patient characteristics of training and testing datasets.
Training Dataset (prostates= 6)
Age 61 ± 9
Prostate Volume (cm2) 82.3 ± 26.0
Primary Lesion Largest Dimension (cm) 2.79 ± 1.1
Secondary Lesion Largest Dimension (cm) 1.0 ± 0.4
Gleason 6 1
Gleason 7a 3
Gleason 7b 2
Gleason 8-10 0
Testing Dataset (prostates= 3)
Age 72 ± 7
Prostate Volume (cm2) 96.4 ± 23.3
Primary Lesion Largest Dimension (cm) 1.9 ± 1.0
Secondary Lesion Largest Dimension (cm) 1.2 ± 0.6
Gleason 6 0
Gleason 7a 2
Gleason 7b 1
Gleason 8-10 0
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13mm by 3mm. With an energy output per bifurcated fiber bundle of
27.5 mJ/pulse, the total energy output was 55mJ/pulse. Based on the
fiber bundle end surface area and energy output, the energy density
maximum was 70.5mJ/cm2. Thus, the fiber bundle setup and energy
output is acceptable as the maximum permissible exposure for this laser
is 100mJ/cm2 [47].
For PAT, the TRUS probe determines the imaging resolution. We
assessed the C9-5ICT TRUS probe’s US and PAT beam full width at half
maximum (FWHM) with a custom sample holder (Fig. 3B) which con-
tained 25 μm tungsten wire at 11, 19, and 26mm from the transducer
(Fig. 3C). As expected, the US axial FWHM remained relatively constant
over depth while the lateral FWHM increased (Fig. 3D and E). The PAT
axial FWHM was larger compared to US while the PAT lateral FWHM
was similar to US, except at 19mm. These results are consistent with
expected resolution for a TRUS transducer array with a center fre-
quency of 7.8 MHz.
Lastly, the peak signal-to-noise ratio (pSNR) of the PA absorbers’ US
and 1064 nm and 1197 nm PAT were assessed using phantoms
(Fig. 3F). Heat shrink tube (HT) is a broad-spectrum, strong absorber
used here as a control, while polyethylene tube (PT) and coagulated
human blood that was 1–2 h old in 1% agar gel was used for the
prostate biomarkers of lipid and hemoglobin. The pSNR for blood was
shown to be statistically different between all imaging channels. For HT
and PT, pSNR for 1064 nm and 1197 nm PAT were not shown to be
statistically different while a difference was shown between PAT and
US channels.
3.2. Thresholding-based analysis is ineffective for identifying prostate
cancer biopsy targets
Intensity thresholding for identifying PCa targets was initially ap-
plied due to recent in vivo PAT imaging study of prostate angiogenesis
which utilized an intensity-based analysis [34]. For assessing intensity
thresholding for identifying PCa-associated signal, we determined the
minimum, average, and maximum signal intensities for PCa and depth-
matched benign PAT ROIs (Fig. 4A). To include only PCa-specific signal
after thresholding, the average maximum signal intensities for the
1064 nm and 1197 nm benign ROIs were used as the minimum cutoff
for PCa-specific pixel identification. For 1064 nm PAT images, the
threshold was set at 9.9 (log scale), while 8.8 was the threshold for
1197 nm PAT images. This approach results in no signal for identifying
prostate biopsy targets in the PCa tissue (Fig. 4B and C). This is ex-
pected as the PCa and depth-matched benign ROIs’ minimum, average,
and maximum values are not statistically different (Fig. 4A). Based on
these results, an alternative approach is needed for identifying targets
for the prostate biopsy.
3.3. K-means clustering feature learning of PAT texture patches
demonstrates that 1197 nm photoacoustic tomography does not uniquely
contribute to clustering results
Besides intensity-based analysis, prior work involving PAT of
human prostates for the purpose of distinguishing malignant versus
benign tissue includes applying multispectral deconvolution, frequency
analysis, and deep neural nets with Greedy feature selection to a dataset
of axially-sectioned, ex vivo human prostates [39–41]. Unfortunately,
Fig. 3. Photoacoustic and Ultrasound
Tomography Imaging System Performance. (A)
Illumination area of 1064 and 1197 nm pulsed
laser light at 1 cm from the fiber bundle ends.
(B) Experimental setup to determine imaging
resolution. UST+BFB: ultrasound transducer
with bifurcated fiber bundle. (C)
Representative US image of 25 μm tungsten
wire. Wires were centered relative to the
transducer array for analysis. Each group has
n=5. Scale bar: 1 cm. (D,E) Axial and lateral
resolution of the US and PAT system when
imaging 25 μm tungsten wire at depths (d) of
11, 19, and 26mm below the US transducer
array. (F) pSNR of 1064 and 1197 nm imaging
of heat shrink tube (HT), polyethylene tube
(PT), and coagulated human blood. Applies to
all panels: each group has n= 5. * =
p < 0.05; ** = p < 0.001; *** =
p < 0.0001.
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multispectral deconvolution cannot be applied here as two PAT chan-
nels are not sufficient as there are at least three endogenous PA ab-
sorbers present, i.e. hemoglobin, lipid, and water [30]. Additionally,
with two PAT and one US imaging channel, we are limited in machine
learning approaches without reformatting the data [42,43]. To re-
format the data for k-means clustering feature learning, the
Fig. 4. Thresholding-based Analysis Is
Ineffective for Identifying Prostate Cancer
Biopsy Targets. (A) Signal intensity character-
istics for tumor and matched benign ROI.
Tumor and benign ROI were not statistically
different. Each data point consists of at least
n= 12. (B) 1064 nm and (C) 1197 nm re-
presentative PAT images that have been thre-
sholded with the maximum average benign ROI
measurement. Prostatic (green) and tumor
tissue (red) are outlined. No biopsy targets
were identified with this method of analysis.
Applies to all panels: scale bar= 1 cm.
Fig. 5. Texture-based K-means Clustering
Feature Learning. (A) Example whole mount
histopathology slide with demarcated tumor
margins (red line). (B) US and (C) 1064 nm
PAT images that best match the whole mount
histopathology slide in A are shown. (D)
Texture patch (x) generation involves de-
termining optimum patch size (w) and step size
between patches (s). Patches are sequentially
created from left to right and then top to
bottom of the US and PAT images. (E) The
patches are processed to a format that is ap-
propriate for k-means clustering. (F) Raw PCa-
related cluster output from k-means clustering
feature learning of training set for US and PAT
images in B and C. (G) Raw PCa-related cluster
output converted to density heat map with
thresholding. Signal corresponds to left pos-
terior tumor foci in A. Applies to all panels:
scale bar= 1 cm; Prostate margin: green line;
Posterior tumor foci: red line.
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histopathology slice-matched PAT and US images (Fig. 5A–C) were
initially converted from an image format to a format appropriate for k-
means clustering (Fig. 5D and E). Texture patches were converted to
row-wise data with neighborhood features in each column. The patches
were five-by-five and considered column-wise from left to right. The
step size between each patch was one. The patch size and step was
chosen from prior published work [43]. Following reformatting the
training dataset was dimensionally reduced using principal component
analysis for the PAT channels alone. The top 50% of the major principal
components were included for feature learning.
After reformatting and dimensionally reducing the data, the feature
learning was performed using k-means clustering with the open source
library VLFeat (0.9.20) [48] with k= 100. Since strong correlation
between 1064 nm and 1197 nm PAT of hemoglobin and lipid was
present (Fig. 3F), feature learning was performed on 1064 nm PAT with
US and 1197 nm PAT with US (Fig. 6) to determine the clustering
contribution from each PAT channel. The PCa- related features were
manually chosen in the training dataset based on overlap with the PCa
ROI in the ground truth histopathology slices. Next, the learned feature
cluster centers were used to cluster the reformatted and dimensionally-
reduced data in the testing dataset. The testing dataset was matched to
the closest learned cluster center. The testing data that was clustered
into the PCa-related feature clusters was then assessed for the clustering
contribution.
As shown in Fig. 6, the original 1064 nm and 1197 nm PAT images
are strongly correlated. For the testing cluster outputs, the PCa-related
clusters are also similar except that there is more non-specific PCa
cluster signal in the 1197 nm with US channel results, which could be
due to the signal intensity being approximately an order of magnitude
lower for the 1197 nm PAT versus the 1064 nm PAT (Fig. 6, Col. 2–3).
Therefore, the 1197 nm PAT channel does not provide a unique con-
tribution to identifying PCa biopsy targets, and only the 1064 nm PAT
with US channel should be used for training and testing of prostate
biopsy targets.
3.4. 1064 nm PAT and US texture analysis identifies biopsies targets
Since the learned features are not dependent upon the 1197 nm PAT
channel, analysis was completed using the 1064 nm PAT and US
channels. The cluster centers from the training dataset (n= 28) were
used with the testing dataset (n=12). As angiogenesis is not a specific
biomarker [36], the PCa-associated clusters were not specific to PCa nor
only prostatic tissue (Fig. 6). To overcome non-specific results, we
apply a ten-by-ten density filter to the PCa cluster results. The ten-by-
ten density filter is assignment of 0 to 100 to each pixel based on the
number of pixels assigned to a PCa-related cluster in the nearby 10-by-
10 pixels. Then, non-specific results were removed by thresholding the
density level (Fig. 5G). Finally, the center of mass for groupings of
prostatic signal was calculated to determine where the biopsy core
would be targeted (Fig. 7).
Using center of mass on the density filter of the PCa cluster outputs,
targets were successfully identified for 100% (3/3 prostates) of the
primary PCa tumors in the testing dataset. In addition, 67% (2/3
prostates) of the secondary PCa tumors were targeted by this approach.
A PCa-free histopathology slice was present in the testing dataset
(Fig. 7). A small amount of PCa-associated cluster output was present in
this PCa-free image. The signal was located in the bilateral peripheral
posterior of the prostate. Since signal was present, biopsy targets were
still included. Ultimately, the number of targets from our approach is
ten, eight, and ten targets respectively for patient 1, 2, and 3 in the
testing dataset. For these targets, the percentage of false positive cores
was 40% (4/10), 50% (4/8), and 30% (3/10) cores for the three cases.
Thus, we are able to target multiple locations of each PCa tumor in the
cases with at least two fewer cores than the current clinical gold stan-
dard approach of the systematic 12-core TRUS-GB [11,49].
4. Discussion
Our work presented here shows that k-means clustering feature
learning of 1064 nm PAT and US texture patches can be used to identify
targets for prostate cancer biopsy. For the first time, PAT is utilized
along with supervised machine learning to independently identify
Fig. 6. 1197 nm Photoacoustic Tomography Does Not Uniquely Contribute to Clustering Results. Each PAT channel was tested for its contribution to PCa feature
learning by viewing the results of the testing dataset. Whole mount histopathology slides with the major tumor’s largest dimension from each case in the testing
dataset are shown in the left-most column. The PCa tumor margins are outlined (green) on the histopathology slides by a urogenital pathologist. 1064 nm and
1197 nm PAT images in log scale corresponding to the histopathology slides are displayed in the second and third column with the prostate (green) and tumor margin
(red) outlines matching the histopathology slides. The raw testing results are exhibited in the two right-most columns with the same prostate tissue (red) and tumor
(red) outlines for reference. Applies to all panels: scale bar= 1 cm.
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targets for prostate biopsy in intact human specimens. Previously, sig-
nificant work was performed on an axially-sliced human prostate spe-
cimen PAT dataset looking at multispectral deconvolution, frequency
analysis, and deep neural nets with Greedy feature selection [39–41].
While this work shows the differences between PCa and benign prostate
tissue, the studies’ approaches are still based on user-selected ROIs or
do not show the locations where targets would be suggested compared
to ground truth histopathology slides. Additionally, the experimental
design with sectioned prostate and subsequent transverse plane of
imaging does not adequately challenge PAT and analysis methods on
imaging depth that would be required for clinical translation. Most
recently, an in vivo pilot study of three patients showed correlation of
PAT of blood to vascular changes in prostate tissue with known PCa
[34]. This work relied on intensity-only measurements which are lim-
ited over the depth of the prostate (Fig. 4). Thus, our work presented
here provides an important contribution to the field of PAT of prostates
for the purpose of guiding prostate cancer biopsy.
The analysis approach presented here has some inherent advantages
as only a single PAT and the US channels were utilized. For PAT, pulsed
lasers are necessary to stimulate the resulting acoustic signal [26].
These lasers are typically 10–20 Hz, with our system containing a 10 Hz
laser. If multiple wavelengths or averaging was needed, the frame rate
would then decrease and add more time to the procedure. The ad-
vantage of using multispectral PAT imaging is that deconvolution of the
signal into its endogenous contrast components could be performed.
Whereas, the benefit of averaging multiple frames at one imaging lo-
cation is that the pSNR could be improved, which would improve the
image quality for analysis. As the prostate biopsy is performed on
awake patients and the urologist is manually controlling the US trans-
ducer while the patient can simultaneously move [50], issues with in-
dividual channels overlapping at an imaging location are possible. This
alignment of individual channels is important for analysis purposes.
Our image analysis approach avoids the potential issue of channel
overlap in each frame as only a single PAT wavelength was ultimately
used to determine the prostate biopsy targets. The use of one PAT
wavelength maximizes imaging speed and will limit added time for the
procedure if clinically translated. Additionally, for the first time, we
identify prostate biopsy targets with an imaging and light delivery
scheme that is clinically relevant compared to previously published
work [39–41].
For this preliminary study, inherent limitations are present. Ex vivo
intact fresh prostate specimens were imaged directly after radical
prostatectomy and before formalin fixation. The 1064 nm PAT images’
signal is primarily from the endogenous absorber hemoglobin. The
absorption coefficient of hemoglobin is different for oxy- versus deox-
yhemoglobin [30]. As the prostate no longer has normal perfusion, we
expect the feature learning of in vivo prostate 1064 nm PAT to provide
different cluster centers than in the presented work. Additionally, an
anatomical barrier that is not included in this study is the rectal wall,
which is a highly scattering tissue [51]. Thus to ultimately prove the
utility of this approach, in vivo imaging is necessary to see the analysis
method’s performance with normal anatomy and perfusion.
Another limitation in this study is the use of histopathology slices as
ground truth for the biopsy targets. Differences in the thickness of the
histopathology slides and the PAT/US image frames ex-
ist—histopathology slices are typically only a few microns thick, while
the elevation resolution for TRUS transducers cannot achieve this
thickness [52]. Also, our approach to matching was performed based on
manual measurements [45]. Thus, exact matching for all of the histo-
pathology slice to the appropriate PAT/US image frame is difficult to
achieve.
A final consideration for this work is the light delivery and US
transducer designs [26]. Here we utilize a bifurcated fiber bundle array
at a 60° angle mounted to the US transducer. This design allows for the
least amount of distance from the fiber bundle to the prostate tissue to
limit light divergence and water absorption. However, a pitfall exists
with this setup: an inherent focus of the light at approximately 1 cm
from the fiber bundle and US transducer array (Fig. 3A). For this reason,
Fig. 7. Prostate Biopsy Targets Identified in Testing Dataset. The PCa tumor margins are outlined (green) on the whole mount histopathology slides in the left-most
column. A cancer-free slide was present in patient 1 of the testing dataset. US and 1064 nm PAT images in log scale corresponding to the histopathology slides are
displayed in the second and third column with the prostate (green) and tumor margin (red) outlines matching the histopathology slides. The raw testing results are
exhibited in the fourth column with the same prostate tissue (red) and tumor (red) outlines for reference. The raw data is then shown as a density heat map in the fifth
column. Center of mass (green circle) of the density signal marks the targets for hypothetical prostate biopsy core acquisition. In the right-most column, the location
of these targets is displayed on the histopathology slides’ ROI: prostatic tissue (black), prostate cancer (grey), and background (extraprostatic tissue and saline;
white). Applies to all panels: scale bar= 1 cm.
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we believe that the secondary lesion that was not targeted in these
results was due to the tumor’s close proximity to the fiber bundle and
US transducer. This issue could be overcome if an additional imaging
scan was performed with the fiber bundle and TRUS probe farther from
the tissue so that the most posterior tissue would be in the beams’ focus.
If this imaging modality and analysis were used clinically, the urologist
could adjust the probe position in real-time to visualize the location.
5. Conclusions
1064 nm PAT and US texture-based k-means clustering feature
learning successfully provided tumor cluster centers that were validated
in the testing group. The resulting targets delivered a 100% (3/3) and
67% (2/3) sensitivity respectively to primary and secondary lesions
while maintaining a total number of biopsy targets per prostate that is
lower compared to the number of core biopsies acquired during current
prostate biopsy protocols. Therefore, this real-time multimodal imaging
technique with target identification method should be explored further
in vivo to determine its clinical value for improving the sensitivity of
prostate biopsies for the purpose of prostate cancer diagnosis.
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